Prevalence of CYP2C9 polymorphisms in the south of Europe
- 21 April 2009
- journal article
- research article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 9 (5) , 306-310
Abstract
CYP2C9 is a major liver enzyme responsible of the metabolism of many clinically important drugs. The presence of CYP2C9 genetic polymorphisms has been associated with marked interindividual variability in its catalytic activity that could result in drug toxicity. Here we present frequencies of the most common CYP2C9 coding variants CYP2C9*2 (C430T) and CYP2C9*3 (A1075C) in representative samples of four regions from Spain (Basque Country, n=358; Catalonia, n=240; Central Spain, n=190 and Galicia, n=288) and one northern Italian region, (Verona, n=164), which range between 0.125 and 0.165 in the case of CYP2C9*2 and between 0.071 and 0.085 for CYP2C9*3. No significant differences between CYP2C9 allele frequencies were found comparing all the sampled populations. A more extensive comparative analysis using allele frequency data of populations widely spread over Europe was performed, showing significant differences in the CYP2C9*2 allele frequencies distribution between some of the regions, being quite homogeneous in the case of CYP2C9*3 variant. The results obtained show that above 40% of our samples carry a mutate allele, which can result in a poor metabolization of low therapeutic index drugs as oral anticoagulants (warfarin, acenocoumarol), oral antidiabetic drugs and some non-steroidal anti-inflammatory drugs. Our study constitutes both a large (n=1240) and robust allele frequency database on CYP2C9 polymorphisms, which represents one of the most numerous CYP2C9*2 and *3 database existing to date.Keywords
This publication has 25 references indexed in Scilit:
- Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspectsPharmacology & Therapeutics, 2007
- Lower frequency of CYP2C9*2 in Mexican-Americans compared to SpaniardsThe Pharmacogenomics Journal, 2004
- A Comparison of Bayesian Methods for Haplotype Reconstruction from Population Genotype DataThe American Journal of Human Genetics, 2003
- Differential expression and function of CYP2C isoforms in human intestine and liverPharmacogenetics, 2003
- Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populationsBritish Journal of Clinical Pharmacology, 2003
- Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populationsCanadian Journal of Physiology and Pharmacology, 2001
- Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoinBritish Journal of Clinical Pharmacology, 1999
- Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseasesCarcinogenesis, 1999
- Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish PopulationBiochemical and Biophysical Research Communications, 1999
- Simulation of the onset of neuromuscular block based on the early oscillations in the arterial plasma concentrationsEuropean Journal of Clinical Pharmacology, 1997